bluuebunny/crossref_metadata_2025_split huggingface dataset:
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
Authors: Jiang Zefei , Sun Tao , Wang Xiaojia , Liu Qiang , Yan Min , Tong Zhongsheng , Geng Cuizhi , Tang Jinhai , Yin Yongmei , Yu Guohua , Wang Jingfen , Su Wuyun , Wang Shusen , Pan Yueyin , Yang Hua 
Published: June 2022

1102 Background: MRG002 is a novel HER2-targeted ADC, composed of a sugar-modified trastuzumab, MMAE payload and a cleavable vc-linker. MRG002 was effective in HER2-low expressing breast cancer in preclinical studies. Hence, we conducted the phase II study to evaluate the safety and anti-tumor efficacy of MRG002 in HER-low breast cancer. Methods: HER2 low tumor expression was determined by a central lab and had to be immunohistochemistry (IHC)1+ or 2+/ISH-. Eligible patients had advanced/metastatic HER2-low expressing breast cancer that failed standard therapies. MRG002 was administered intravenously once every 3 weeks at the dose of 2.6 mg/kg, until disease progression or unacceptable toxicity which ever occurred first. The primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC). The secondary endpoints were progression-free survival (PFS), disease control rate (DCR), and safety. Results: A total of 56 female patients with HER2-low advanced or metastatic breast cancer were enrolled at the time of data cut-off (Dec 31, 2021) and had received at least one cycle of MRG002. The median age was 55 (30-72) years. Most patients were HER2 IHC1+ (83.9%), hormone receptor positive (HR+) (85.7%), and with a ECOG PS of 1 (57.1%). Twenty-eight patients (50.0%) had received at least 2 lines of chemotherapy and the median treatment was 3. Forty-one patients (73.2%) had visceral metastasis and 31 patients (55.4%) had bone metastasis. The ORR and DCR in 49 evaluable patients were 34.7% and 75.5%, with 17 PR, 20 SD and 12 PD. Subgroup analysis indicated that the ORR was 39.5% (15/38) and DCR was 76.3% (29/38) among the evaluable patients with visceral metastasis. The tumor responses were similar in both the HER2 IHC 1+ and IHC 2+ subgroups, as is 34.1% and 37.5% respectively, which might be attributed to fewer IHC 2+ enrollment in this trial. Although only 8 HR- subjects enrolled in our study, the ORR (37.5%) and DCR (62.5%) is promising in these triple negative BC patients post to ≥2 line therapies. Most common treatment related adverse events (TRAEs) were grade 1 or 2. The most common TRAEs (≥20%) were neutrophil count decreased (53.6%), white blood cell count decreased (48.2%), AST increased (46.4%), alopecia and ALT increased (39.3%), blood lactate dehydrogenase increased(33.9%), GGT increased (32.1%), nausea (32.1%), vomiting (23.2%), constipation (23.2%), diarrhea(23.2%) and hyperglycemia (21.4%). Most common grade ≥3 TRAE(≥10%) was neutrophil count decreased(14.3%). No patients died due to MRG002. Conclusions: MRG002 shows promising efficacyand well tolerated in patients with HER2-low breast cancer. Further evaluation is underway. Clinical trial information: NCT04742153.
Professional development in a Twitter hematology/oncology network for trainees.
Authors: Faisal Muhammad Salman , Anampa-Guzmán Andrea , Desai Aakash , Mohyuddin Ghulam Rehman , Marshall Ariela Lucy 
Published: June 2022

11034 Background: While resources exist to address the needs of graduate medical trainees, online resources to assist trainees with specialty-specific professional development have not been fully developed or described in the past. The Hem-Onc Fellows Network (@HemOncFellows) is an online community for hematology-oncology trainees in all stages of training, including medical students, residents, fellows, and doctoral students. The network's goals are to provide professional development in hematology-oncology, create a community and safe space for hematology-oncology trainees, and amplify the voices and needs of trainees. Methods: The @HemOncFellows Twitter account was created in February of 2021. The hashtag #HOFellows was registered and certified with healthcare Symplur. The network hosts Twitter Spaces (TS) with guests every two weeks and distributes a newsletter. Fifteen TS were held between July 2021 and February 2022. For each TS, a specific topic of professional development was discussed. At least one content expert was invited to each TS to provide additional commentary. Demographics of TS participants and newsletter subscribers were gathered and qualitative and quantitative analysis was performed. Results: Since its inception, the Hem-Onc Fellows Network has grown to more than 2200 followers. Symplur has over 500 #HOFellows tweets from November of 2021 to early February of 2022. The network organized 15 TS: 14 in professional development topics and one meet-and-greet for new matched fellows in December. TS had an average of 41 participants per event. Most participants were United States-based but there were participants from 21 countries worldwide. Forty-eight participants attended three or more spaces, including 15 hem-onc fellows and 17 internal medicine residents. The newsletter has 48 subscribers. Conclusions: We demonstrate that implementing a trainee network on Twitter attracted participation and engagement from a diverse pool of trainees worldwide. TS represents a novel educational tool for engaging trainees and facilitating professional development.
Google search engine analytics for cancer immunotherapy: What patients are searching for on the internet and where they find answers.
Authors: Suresh Neeraj , Rajasekaran Karthik 
Published: June 2022

11036 Background: Immunotherapy in the treatment of cancer has been on the rise and is on the forefront of current cancer research. As such, patients are increasingly turning to the Internet and online resources to answer their questions. For any given Google search, artificial intelligence and machine learning algorithms generate a “People Also Ask” (PAA) section which returns the most commonly associated questions to the original search query, with corresponding websites to answer those questions. Using a search engine optimization (SEO) tool, we determined the most frequently searched terms and questions regarding cancer immunotherapy online, and the websites used to answer them. Methods: The top Google search queries and PAA questions with associated volume metrics were extracted for the terms “immunotherapy” and “cancer immunotherapy” using an SEO tool. PAA questions and corresponding websites were categorized by specific topic and Rothwell’s classification system. Websites were further quality assessed using the Journal of the American Medical Association (JAMA) benchmark criteria. Results: Global searches for cancer immunotherapy increased significantly each year since 2015. Countries with the most search volume were the U.S. (44%), the U.K. (12%), and India (11%). PAAs (n = 674) and the most frequently searched questions regarding cancer immunotherapy, by average monthly search volume (searches per month), were on: definitions/how it works (n = 6.6K, 21.3%), side effects (n = 4.4K, 14.2%), cost (n = 2.9K, 9.4%), immunotherapy vs. chemotherapy (n = 1.8K, 5.8%), drug options (n = 1.7K, 5.5%), signs immunotherapy is working (n = 1.2K, 3.9%), different types of immunotherapy (n = 1.1K, 3.5%), route of administration (n = 800, 2.6%), efficacy/success rate (n = 800, 2.6%), and effect on life expectancy (n = 300, 1.0%). The top cancers that patients searched immunotherapy treatments for were: lung (n = 1.9K, 23.2%), melanoma (n = 1.5K, 18.3%), pancreatic (n = 700, 8.5%), breast (n = 600, 7.3%), and bladder (n = 500, 6.1%). The most queried immunotherapy drugs were Pembrolizumab/Keytruda (n = 87K), Nivolumab/Opdivo (n = 33K), and Ipilimumab/Yervoy (n = 11.1K). Websites used to answer PAA questions were mostly those of academic institutions (n = 294, 43.6%), commercial organizations (n = 167, 24.8%), and government databases (n = 126, 18.7%). Conclusions: The field of cancer immunotherapy is rapidly evolving and patients often look to the Internet to answer their latest questions. Using our findings, academic institutions, commercial organizations, and physicians involved in multi-disciplinary cancer care can cater their patient communications and websites to more directly align with patients’ most common questions and concerns on immunotherapy.
Generating meaningful peer-to-peer engagement through a mentor-led, small group social learning experience on the evolving standards of care for advanced HER2+ breast cancer.
Authors: Shivakumar Latha , Wongus Rukiya , Haimowitz Steven , Shah Lisa , Ye Amanda , Boehmer Leigh 
Published: June 2022

11040 Background: Although the COVID-19 pandemic quickly created a spotlight on distance learning, identifying models that can deliver effective educational programs and best serve the needs of oncology clinicians remains a significant challenge. Methods: We conducted an educational program on the evolving standards of care for advanced HER2+ breast cancer hosted on a novel digital platform that offers a personalized social learning experience which prioritizes engagement, peer-to-peer learning, and mentorship within a small group setting. Results: 87 learners within 10 groups of professionally-connected clinicians participated. Learners progressed through foundational self-study modules, collaborated on asynchronous group challenges, and participated in synchronous live group discussions over six weeks (approximately 4 hours total). Quantitative and qualitative analysis of data extracted from these components highlights the impact of this program (Table). Notably, the learner population was more specialized and engaged than could be expected of a traditional CME program. Feedback suggests strong impact of the live group discussions on learners’ intended practice changes. Additionally, analysis of group challenges and live group discussions revealed several key insights into learner thinking about treatment guidelines, including their differing opinions about the role of surgery/radiation in patient care, uncertainty about the mechanisms of action (MOAs) of discussed therapies, and their apprehension about implementing therapies that may impact the heart and lungs. Conclusions: The outcomes from this analysis highlight the utility of this type of social learning platform to create a safe, supportive learning environment that encourages multiple real-time and asynchronous interactions and shared experiences between clinicians who treat patients with advanced HER2+ breast cancer, as well as offering unique and convenient mentoring opportunities for clinicians interested in leading these digital small groups. Program impact.[Table: see text]
Comparing online engagement and academic impact of lung cancer research: An altmetric attention score and PlumX analysis.
Authors: Muthiah Arun , Muthiah Chandrasekar , Wei Chapman , Khan Hina 
Published: June 2022

11044 Background: Social media has proven vital in the rapid dissemination of literature to medical professionals and the public. In recent years, seminal research articles have yielded breakthrough therapies for lung cancer, including targeted drugs and unique immunotherapy-based combinations. New metrics such as the Altmetric Attention score (AAS) and PlumX Impact score capture interactions through social media and other public forums and serve as swifter counterparts to citations, which can take years to accrue. In this study, we characterize and compare AAS, PlumX and traditional bibliometrics (citation count, impact factor [IF]) of the top 100 trending articles on lung cancer. Methods: The 100 articles with the highest AAS featuring the keywords “lung cancer” between 01/2019 and 12/2021 were identified via Altmetric explorer. AAS, open access status, article type, topic, year and continent of publication were collected. PlumX and citation count were identified via Scopus database. Analysis included Spearman correlation coefficients and ANOVA. Results: A majority of the 100 articles were original investigations, of which 40% were RCTs, 22% retrospective cohort, 14% prospective, 9% basic science, 8% cross-sectional and 6% genome-wide association studies. Most articles focused on NSCLC (59%) and were conducted in North America (44%); 13% were in Europe, 36% multi-continental and the remainder < 5% each. PlumX positively correlated with both citation count (p <.001, r =.765) and IF (p <.001, r =.581). AAS did not correlate with citation or IF. Articles on guidelines (p <.001) and screening (p <.001) were associated with higher AAS in comparison to other article types and topics, respectively. Basic science articles were associated with a higher PlumX (p <.001) in comparison to others article topics. Year and continent of publication did not impact PlumX or AAS. Open access status did not correlate with PlumX or AAS. Conclusions: In our study, PlumX scores strongly correlated with citations and IF for recently published articles on lung cancer; this mirrors trends in other specialties. PlumX may be predictive in terms of academic impact, making it valuable to the research community. Though AAS did not correlate with traditional bibliometrics, its association with guidelines and screening articles suggests AAS may reflect interactions amongst a broader community (oncologic and non-oncologic clinicians). With the growing use of social media, the continued exploration of alternative metrics will play a role in understanding readership and fields of interest in lung cancer and in anticipating academic impact.[Table: see text]
The impact of diversity, equity, and inclusion training in an independent community oncology practice.
Authors: Fleming Mark T. , Lewis Tifany , Lyons Kristina , Poole Roshonda , Prillaman Christina 
Published: June 2022

11057 Background: Historically, Diversity, Equity, and Inclusion (DEI) efforts have largely been left out of private practice medical facilities – mainly present in large academic hospital centers. Virginia Oncology Associates (VOA), a member of The US Oncology Network, is an independent community oncology and hematology practice specializing in the diagnosis and treatment of cancer and blood disorders. VOA has approximately 600 total employees consisting of physicians and clinical and non-clinical staff. In August of 2020, VOA launched an initiative to foster a culture of inclusion with the creation of its Inclusion Council (IC). Sixteen employees’, both clinical (3 physicians) and non-clinical, were chosen to participate. The council reports to VOA’s joint policy board. Methods: The council partnered with an outside organization, Virginia’s Center for Inclusive Communities, to launch a practice-wide DEI training program focusing on unconscious bias and microaggression. The training was initially planned to be in person, but due to the constraints of the COVID pandemic, the training was performed using a virtual platform. The members of IC attended three two-hour sessions while other staff members and physicians were mandated to participate in at least one training session. After completion of the sessions, a survey was sent to all employees and physicians to measure the impact of DEI training. All employees were also given the opportunity to provide additional, anonymous, written feedback. Results: Table. A total of 169 employees responded. 72% of respondents agreed or strongly agreed that the program increased awareness of unconscious bias and microaggression, 67% felt that the program helps foster a culture of inclusion in the workplace, and 66% of respondents felt that the program met expectations. Conclusions: DEI efforts are vital in all aspects of health care delivery and oncology settings. DEI training met staff expectations and positively fostered a culture of inclusion by bringing attention to unconscious bias and microaggression in a community oncology practice.[Table: see text]
Gemcitabine-docetaxel in patients with relapsed high-grade osteosarcoma after first-line treatment with high-dose ifosfamide: A retrospective multicenter study.
Authors: Pionelli Maria Grazia , Asaftei Sebastian Dorin , Meazza Cristina , Longhi Alessandra , Tamburini Angela , Coccoli Luca , Merlini Alessandra , Cagnazzo Celeste , Tirtei Tirtei , Fagioli Franca 
Published: June 2022

11520 Background: Currently, there is no accepted standard chemotherapy regimen for recurrent osteosarcoma. We performed a retrospective study to evaluate the effectiveness, toxicity and clinical benefit of second line therapy with Gemcitabine (G) in combination with Docetaxel (D), in patients with relapsed high-grade osteosarcoma who have been previously treated with High-dose Ifosfamide (HD-IFO) during first-line treatment (ClinicalTrials ID: NCT04651179). Methods: Patients were eligible to the analysis according to the following criteria: episode of first relapse of osteosarcoma, previous first line treatment according to poor responders’ arm of ISG-AIEOP OS 2 Protocol based on methotrexate, cisplatin, doxorubicin and HD-IFO (3gr/m2/day, day 1-5) ± Mifamurtide, presence of measurable disease according to RECIST 1.1, treatment with at least two cycles of Gemcitabine 900 mg/m2/day, days 1 and 8 and Docetaxel 75 mg/m2 day 8 every 21 days. Primary objective: overall survival (OS) at 12 months; secondary objectives: overall response rate (ORR) (complete response + partial response), progression-free survival (PFS) at 6-12 months, toxicity and quality of life. Results: 14 patients were included in the analysis. All patients were previously treated according to poor responders’ arm of ISG-AIEOP OS 2 Protocol, 7/14 (50%) of them received Mifamurtide. Most of patients (12/14, 86%) received 4 GD cycles and the total number of cycles administered was 60. Median OS was 20 months (range 11-69); OS at 12 and 24 months was 84% (95% CI 65-100) and 51% (95% CI 22-79), respectively; ORR were 35,7% after six cycles. Median PFS was 12 months (range 2-69); 6-months and 12-months PFS were 86% (95% CI 67-100) and 56% (30-83) respectively. For 8/14 (57%) patients a surgical approach was feasible after 2 and 6 GD cycles. Previous use of Mifamurtide correlate with a better 6-months PFS rate (100% vs 57%, P = 0.0011). Also, amelioration of ECOG/Lansky score showed a positive correlation with both PFS (P = 0.01) and OS (P = 0.04). No extra-hematological toxicities grade ≥3 was observed according to CTCAE v4.03 criteria. Conclusions: This trial confirms that GD combination has an anti-tumor activity for relapsed high-grade osteosarcoma with a well-tolerated toxicity profile. Furthermore, GD guarantee a surgical tumor remotion for patients with a chemo-resistant disease such as patients previously treated with a poor responders’ arm improving their OS and PFS rate. Promising results for patients previously treated with Mifamurtide need to be confirmed in future trials. Clinical trial information: NCT04651179.
Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma.
Authors: Seeber Andreas , Elliott Andrew , Modiano Jaime , Untergasser Gerold , von Mehren Margaret , Rosenberg Andrew , Khushman Moh'd , Dizon Don S. , Riedel Richard F. , Trent Jonathan C. , Zimmer Kai , Lagos Galina , DeNardo Bradley , Sarver Aaron , Puccini Alberto , Walker Phillip , Oberley Matthew James , Korn Wolfgang Michael , Wolf Domink , Kocher Florian 
Published: June 2022

11525 Background: Osteosarcoma (OS) incidence is characterized by a bimodal age distribution, with peaks in early adolescence and in adults > 65 years of age. In contrast to adolescents, OS in adults is frequently considered as a secondary neoplasm (i.e., transformation of Paget´s disease of the bone, radiation induced). Yet, the literature is scarce regarding the impact of age on the molecular landscape of OS. Herein, we sought to explore the association between age and the genomic profile as well as the tumor immune microenvironment (TME) in a large cohort of OS patients. Methods: 208 specimens were centrally analysed at the Caris Life Sciences laboratory with DNA seq (NextSeq, 592 gene panel or NovaSeq, whole-exome sequencing), RNA seq (Archer fusion panel or whole-transcriptome sequencing) and immunohistochemistry (IHC). RNA deconvolution and differential expression analyses were performed using the Microenvironment Cell Populations counter method for quantification of immune cell populations and gene expression profiling. The cohort was stratified into three distinct age groups (< 25 years [n = 83], 25-45 years [n = 58], > 45 years [67]). Results: Overall, the most frequently detected mutations were in TP53 (37%), RB1 (13%), ATRX (9%), TERT (6%), PTEN (5%), PIK3CA (4%) and KMT2D (3%). Copy number alterations were most frequently detected in CDK4 (12%), LRIG3 (11%), FLCN (11%), MDM2 (9%), CCND3 (9%), VEGFA (8%), TFEB (8%). Interestingly, age-based stratification revealed an increased frequency of FLCN (19.7 vs 4.7%, p < 0.01), CCND3 (13.9 vs 3.1%, p < 0.05), and HSP90AB1 (11.3 vs 0.0%, p < 0.01), alterations in patients < 25 years compared to > 45 years. TME analysis revealed that patients > 45 years have decreased B-cell abundance compared to patients < 25 years (2.9-fold decrease, p < 0.05) and 25-45 years (4.8-fold decrease, p < 0.05). Although not statistically significant, median transcriptional expression of PD-L1 was numerically increased in patients > 45 years (1.8-fold compared to 25-45 years, p = 0.17; 2.0-fold compared to < 25 years, p = 0.27), which was consistent with increasing rates of IHC PD-L1 expression with age (5.3%, 9.4%, and 17.5%, respectively, p = 0.06). Conclusions: To the best of our knowledge, this study represents the largest cohort of molecularly characterized OS. Age-associated differences in the genetic landscape and TME composition, including increased gene amplifications observed in younger patients and decreased B-cell abundance in older patients, might suggest fundamental underlying molecular and biological differences.